LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Transperitoneal repair of a juxtarenal abdominal aortic aneurysm and co-existent horseshoe kidney with division of the renal isthmus.

    Hajibandeh, Shahin / Hajibandeh, Shahab / Johnpulle, Michelle / Perricone, Vittorio

    Journal of surgical case reports

    2015  Volume 2015, Issue 10

    Abstract: The co-existence of abdominal aortic aneurysm (AAA) and horseshoe kidney (HSK) is rare. We report a 67-year-old man with an expanding juxtarenal AAA associated with a HSK. The aneurysm had a severely angulated neck and contained a significant amount of ... ...

    Abstract The co-existence of abdominal aortic aneurysm (AAA) and horseshoe kidney (HSK) is rare. We report a 67-year-old man with an expanding juxtarenal AAA associated with a HSK. The aneurysm had a severely angulated neck and contained a significant amount of mural thrombus. The isthmus of HSK closely lied over the aneurysm, making its exposure extremely difficult. The aneurysm was successfully repaired using transperitoneal approach with division of the renal isthmus and without any need for the renal artery reconstruction. Despite the potential complications, particularly renal insufficiency, associated with division of the renal isthmus and suprarenal cross-clamping of the abdominal aorta, in our case, post-operative period was uneventful and the patient's recovery was satisfactory.
    Language English
    Publishing date 2015-10-28
    Publishing country England
    Document type Case Reports
    ISSN 2042-8812
    ISSN 2042-8812
    DOI 10.1093/jscr/rjv134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.

    Samson, Adel / West, Emma J / Carmichael, Jonathan / Scott, Karen J / Turnbull, Samantha / Kuszlewicz, Bethany / Dave, Rajiv V / Peckham-Cooper, Adam / Tidswell, Emma / Kingston, Jennifer / Johnpulle, Michelle / da Silva, Barbara / Jennings, Victoria A / Bendjama, Kaidre / Stojkowitz, Nicolas / Lusky, Monika / Prasad, K R / Toogood, Giles J / Auer, Rebecca /
    Bell, John / Twelves, Chris J / Harrington, Kevin J / Vile, Richard G / Pandha, Hardev / Errington-Mais, Fiona / Ralph, Christy / Newton, Darren J / Anthoney, Alan / Melcher, Alan A / Collinson, Fiona

    Cancer immunology research

    2022  Volume 10, Issue 6, Page(s) 745–756

    Abstract: Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic ... ...

    Abstract Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials. We report the results of a single-center, nonrandomized biological end point study (trial registration: EudraCT number 2012-000704-15), which builds on the success of the presurgical intravenous delivery of oncolytic viruses to tumors. Nine patients with either colorectal cancer liver metastases or metastatic melanoma were treated with a single intravenous infusion of Pexa-Vec ahead of planned surgical resection of the metastases. Grade 3 and 4 Pexa-Vec-associated side effects were lymphopaenia and neutropaenia. Pexa-Vec was peripherally carried in plasma and was not associated with peripheral blood mononuclear cells. Upon surgical resection, Pexa-Vec was found in the majority of analyzed tumors. Pexa-Vec therapy associated with IFNα secretion, chemokine induction, and resulted in transient innate and long-lived adaptive anticancer immunity. In the 2 patients with significant and complete tumor necrosis, a reduction in the peripheral T-cell receptor diversity was observed at the time of surgery. These results support the development of presurgical oncolytic vaccinia virus-based therapies to stimulate anticancer immunity and increase the chances to cure patients with cancer.
    MeSH term(s) Humans ; Leukocytes, Mononuclear ; Liver Neoplasms/therapy ; Neoadjuvant Therapy ; Oncolytic Virotherapy/methods ; Oncolytic Viruses/genetics ; Vaccinia virus/genetics
    Language English
    Publishing date 2022-04-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-21-0171
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top